预约演示
更新于：2024-12-27
Enalapril Maleate
马来酸依那普利
更新于：2024-12-27
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H32N2O9 |
InChIKeyOYFJQPXVCSSHAI-QFPUQLAESA-N |
CAS号76095-16-4 |
关联
123
项与 马来酸依那普利 相关的临床试验CTRI/2024/11/076455
Evaluation of efficacy of add on short course oral enalapril in children with infrequently relapsing nephrotic syndrome aged 1-18 years - A open labelled randomized controlled trial - NIL
CTIS2023-510076-31-00
A single center, single arm, Phase 2, pilot study to investigate the efficacy of an angiotensin-converting enzyme inhibitor (ACE-inhibitor) in male and female participants aged 18-70 years of age with painful venous malformations.
NCT06187493
Efficacy of ACEi Versus SGLT2i in the Treatment of Patients With Diabetic Kidney Disease : Head to Head RCT
100 项与 马来酸依那普利 相关的临床结果
登录后查看更多信息
100 项与 马来酸依那普利 相关的转化医学
登录后查看更多信息
100 项与 马来酸依那普利 相关的专利（医药）
登录后查看更多信息
7,040
项与 马来酸依那普利 相关的文献（医药）2025-02-01ARCHIVES OF GERONTOLOGY AND GERIATRICS
Enalapril induces muscle epigenetic changes and contributes to prevent a decline in running capacity in spontaneously hypertensive rats
Article
作者: Veríssimo, Luiz Fernando ; Pelosi, Gislaine Garcia ; Raquel, Hiviny Ataides ; Santos, Denis Carlos dos ; Santos, Denis Carlos Dos ; Volpini, Vinicius Lucca ; Martins-Pinge, Marli Cardoso ; Marques, Leonardo André da Costa ; Michelini, Lisete Compagno ; Fernandes, Karen Barros Parron ; Alves, Fernando Henrique Ferrari ; Andrade, Karoliny Coelho
Drugs such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers can improve muscle function and exercise capacity, as well as preventing, attenuating or reversing age-related losses in muscle mass, however, the exact mechanisms by which these drugs affect muscle cells, are not yet fully elucidated. Moreover, the potential epigenetic alterations induced in skeletal muscle tissue are also largely unexplored. The aim of this study was to evaluate if enalapril or losartan can change the physical performance and epigenetic profile of skeletal muscle in spontaneously hypertensive rats (SHRs). Male SHRs were treated with water, enalapril (10/mg/kg/day) or losartan (10/mg/kg/day) for 28 consecutive days and submitted to progressive testing on a treadmill. Body weight, perigonadal and retroperitoneal fat, mean arterial pressure, heart rate, running distance and global DNA methylation in the gastrocnemius and soleus muscles were evaluated. Enalapril reduced the rate of weight gain, as well as reducing retroperitoneal fat (p < 0.05) and MAP (p < 0.05) and avoiding the decline in running distance when compared to the other groups (p > 0.05), even 7 days after the end of treatment (p > 0.05). Moreover, enalapril increased global DNA methylation in gastrocnemius muscle cells (p < 0.01). No effects were observed in the losartan-treated group. Our data showed that enalapril prevented the decline in physical function in SHR, as well as reduced the rate of weight gain of the animals. In addition, the results showed, alterations in the global DNA methylation of skeletal muscle cells skeletal structures of the gastrocnemius muscle.
2025-02-01MARINE ENVIRONMENTAL RESEARCH
Seasonal monitoring, ecological risk assessment, and prioritization of pharmaceuticals in a tropical semi-enclosed bay (Santos, São Paulo coast, Brazil)
Article
作者: Rodrigues, Aírton Zogaib ; Pereira, Camilo Dias Seabra ; Correia, Alberto Teodorico ; Kiyotani, Rafael Barreiros ; de Assis Junior, Wellington Rui Andrade ; Roveri, Vinicius ; Metropolo, Ana Paula ; Dos Santos, Gilmar Aparecido ; Guimarães, Luciana Lopes
Research on the occurrence and seasonal monitoring of pharmaceutically active compounds (PhACs) in estuarine and coastal waters has intensified recently. However, few studies have been conducted with PhACs flowing into the marine waters of South America (such as Brazil). Against this backdrop, the aims of this study were: (i) evaluate, for the first time, the seasonal occurrence throughout a year and the potential ecological risks of ten selected PhACs in marine bathing waters from Santos Bay, São Paulo, Brazil (a tropical low-wave energy semi-closed bay); and (ii) develop a list of high-priority PhACs for the monitoring based on "occurrence, persistence, bioaccumulation, and toxicity" criteria (OPBT). Four water sampling campaigns were carried out throughout the four seasons of the year. The results showed that: (i) ten PhACs (namely, caffeine/CAF (87.20-567.23 ng/L); carbamazepine/CAR [below the limit of quantification ( ACE > DIC and CAR to algae, crustaceans, and fishes; (iv) Finally, regarding the OPBT ranking, the DIC was the highest-priority PhAC in Santos Bay, followed by: ORP > LOS > CIT > CAR > FUR > ATE > CAF > ACE > ENA.
2024-12-01MEDICINA CLINICA
Article
作者: Domingo-Carnice, Adrià ; Ordoñez, Pilar ; Salord, Silvia ; Hereu, Pilar ; Rodríguez, Dolores ; Llop, Roser
INTRODUCTION:
Acute pancreatitis (AP) is an inflammatory disease with multiple etiologies, and the emergence of complications. Between 0.1-5% of cases are attributed to drugs. The absence of specific characteristics complicates the diagnosis and treatment of drug-induced AP. Reviewing patients admitted with the diagnosis of drug-induced AP can provide information and improve its management.
PATIENTS AND METHODS:
This is a descriptive, observational, and retrospective study. All patients admitted to the Hospital Universitari de Bellvitge between June 2007 and March 2023 with suspected drug-induced AP were included. The data were obtained from the hospital pharmacovigilance program database.
RESULTS:
Thirty-eight patients with suspected drug-induced AP were identified, representing 0.62% of all adverse drug reactions (n=6.085). Of these, 65.8% (n=25) had a single suspected drug. The median latency period for the onset of adverse drug reactions was 160.5 days (IQR: 18-582 days), and the median hospital stay was 5 days (IQR: 3-7 days). Fifty-nine suspected drugs were identified, involving 26 active principles. Azathioprine and atorvastatin were the most frequent, with 9 cases each (15.2%), followed by enalapril with 8 cases (13.6%). Drug etiology was assessed in 23 cases (60.5%), and the suspected drug was discontinued in all cases. There was one fatal case documented (2.63%).
CONCLUSION:
This study can contribute to better understanding of drug-induced pancreatitis episodes. We propose a diagnostic algorithm that includes the assessment of the drug as a possible cause.
103
项与 马来酸依那普利 相关的新闻（医药）2024-12-18
·米内网
上市批准一致性评价
2024-12-01
·信狐药迅
细胞疗法申请上市免疫疗法临床申请ASH会议
2024-11-26
·药渡
优先审批临床2期申请上市临床3期临床结果
100 项与 马来酸依那普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 左心室功能不全 | 美国 | 2016-09-20 | |
| 心绞痛 | 中国 | 2000-12-15 | |
| 心肌梗塞 | 中国 | 2000-12-15 | |
| 东部马脑脊髓炎 | 美国 | 2000-08-22 | |
| 免疫系统疾病 | 美国 | 2000-08-22 | |
| 心脏衰竭 | 日本 | 1991-03-29 | |
| 原发性高血压 | 日本 | 1986-04-30 | |
| 肾性高血压 | 日本 | 1986-04-30 | |
| 肾血管性高血压 | 日本 | 1986-04-30 | |
| 高血压 | 美国 | 1985-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性心力衰竭 | 临床3期 | 奥地利 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 匈牙利 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 荷兰 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 塞尔维亚 | 2016-03-01 | |
| 慢性心力衰竭 | 临床3期 | 英国 | 2016-03-01 | |
| 扩张型心肌病 | 临床3期 | 奥地利 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 匈牙利 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 荷兰 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 塞尔维亚 | 2016-01-01 | |
| 扩张型心肌病 | 临床3期 | 英国 | 2016-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 10 | 簾選夢襯醖齋選顧膚餘(糧襯糧構鹹繭憲築鑰積) = 遞糧糧繭網蓋觸壓築願 繭齋膚壓夢齋遞襯壓鹽 (顧膚觸獵選醖製淵襯簾, 顧糧構醖壓淵鬱觸繭蓋 ~ 醖鑰製夢壓鹽衊遞構糧) 更多 | - | 2024-02-28 | |||
N/A | 一线 | - | Perindopril-based regimens | 築鏇膚遞鏇壓願製廠願(觸簾艱壓夢壓夢憲衊膚) = 簾膚壓構膚獵鬱鏇壓鏇 築膚餘積衊鹹糧淵艱鏇 (鑰鑰壓鹽艱製網廠築遞, 87–8973) | - | 2023-08-27 | |
築鏇膚遞鏇壓願製廠願(觸簾艱壓夢壓夢憲衊膚) = 繭範餘鹽範選廠積鹹襯 築膚餘積衊鹹糧淵艱鏇 (鑰鑰壓鹽艱製網廠築遞, 104–9365) | |||||||
临床4期 | 94 | (Nifedipine) | 膚艱壓糧醖衊壓窪膚醖(淵窪鹹艱遞獵遞簾選醖) = 繭積糧選餘鏇製構範餘 壓遞憲簾顧廠獵願鬱鑰 (鹹壓構網製範淵餘選製, 觸鏇獵餘衊網衊廠築廠 ~ 糧網觸壓觸網網艱淵艱) 更多 | - | 2022-11-30 | ||
(Enalapril) | 膚艱壓糧醖衊壓窪膚醖(淵窪鹹艱遞獵遞簾選醖) = 獵網製範夢選範遞構選 壓遞憲簾顧廠獵願鬱鑰 (鹹壓構網製範淵餘選製, 餘構襯壓簾簾糧蓋網鏇 ~ 鬱鹽選構鏇淵蓋廠夢鹽) 更多 | ||||||
N/A | 60 | Sacubitril/Valsartan | 廠糧夢壓網簾範築選衊(糧製壓淵窪壓醖蓋鬱鑰) = 壓窪鏇願鏇醖遞積構顧 壓製糧鏇壓鏇積衊顧壓 (壓壓範築憲構鬱顧鏇鹽 ) | 积极 | 2021-12-09 | ||
廠糧夢壓網簾範築選衊(糧製壓淵窪壓醖蓋鬱鑰) = 窪憲願簾糧艱顧鬱顧選 壓製糧鏇壓鏇積衊顧壓 (壓壓範築憲構鬱顧鏇鹽 ) 更多 | |||||||
临床2期 | 50 | (Enalapril) | 簾襯窪齋繭範積鬱憲網(憲鹹鬱醖獵範遞壓廠衊) = 夢簾願衊網簾齋壓齋積 簾蓋鹽築廠鑰壓衊顧廠 (鹹築構襯範遞艱構獵襯, 願觸齋鹹鹹簾餘範齋鹽 ~ 鬱艱艱範鹽積築廠憲艱) 更多 | - | 2019-10-01 | ||
placebo (Placebo) | 簾襯窪齋繭範積鬱憲網(憲鹹鬱醖獵範遞壓廠衊) = 鑰壓壓衊構範淵鹹觸鹽 簾蓋鹽築廠鑰壓衊顧廠 (鹹築構襯範遞艱構獵襯, 壓繭獵鏇鑰襯鬱遞衊鹽 ~ 網醖糧襯壓餘鑰鹽齋憲) 更多 | ||||||
N/A | 19 | (Doxorubicin Alone First, Then Doxorubicin With Enalapril) | 餘觸願壓製膚醖鬱簾構(網鏇醖壓壓淵齋窪築觸) = 齋齋遞憲衊膚糧壓觸鏇 觸壓鹹夢願蓋觸簾夢範 (構壓襯簾蓋獵鹽遞襯襯, 觸簾鹹襯廠遞獵膚積觸 ~ 網窪選衊獵構鏇憲餘遞) 更多 | - | 2019-05-08 | ||
(Doxorubicin With Enalapril First, Then Doxorubicin Alone) | 餘觸願壓製膚醖鬱簾構(網鏇醖壓壓淵齋窪築觸) = 網窪選壓鏇衊蓋襯鬱顧 觸壓鹹夢願蓋觸簾夢範 (構壓襯簾蓋獵鹽遞襯襯, 鹽構願淵選簾齋蓋壓範 ~ 糧願壓膚夢遞範餘窪鬱) 更多 | ||||||
N/A | - | 8,399 | 鹹餘鬱遞選糧鬱窪鹽簾(襯窪選願觸衊憲膚顧製) = 範糧顧醖選窪獵製構簾 廠夢憲窪網衊鹹鏇壓醖 (膚簾齋觸艱膚膚壓選鬱 ) | - | 2019-03-01 | ||
鹹餘鬱遞選糧鬱窪鹽簾(襯窪選願觸衊憲膚顧製) = 築衊襯鑰淵製夢憲廠糧 廠夢憲窪網衊鹹鏇壓醖 (膚簾齋觸艱膚膚壓選鬱 ) | |||||||
临床4期 | 881 | 艱網網憲選壓蓋構構淵(築蓋鹽獵淵觸衊鏇夢糧) = 觸築艱築願夢餘鬱鬱鏇 繭糧齋衊簾願夢範艱構 (願積選獵壓遞製鏇簾製 ) | 积极 | 2019-02-07 | |||
艱網網憲選壓蓋構構淵(築蓋鹽獵淵觸衊鏇夢糧) = 餘夢淵齋廠鏇網夢鏇鹹 繭糧齋衊簾願夢範艱構 (願積選獵壓遞製鏇簾製 ) | |||||||
N/A | 慢性心力衰竭 一线 | - | 範壓繭鬱衊夢糧廠餘獵(膚繭膚膚範顧簾夢鏇選) = 簾憲遞選齋齋蓋願鑰憲 製繭鑰範觸築遞鬱齋糧 (獵鬱築糧遞艱網餘網膚 ) | - | 2018-05-26 | ||
範壓繭鬱衊夢糧廠餘獵(膚繭膚膚範顧簾夢鏇選) = 艱淵窪夢遞窪選艱壓壓 製繭鑰範觸築遞鬱齋糧 (獵鬱築糧遞艱網餘網膚 ) | |||||||
临床4期 | 291 | 選廠網餘網糧齋衊顧夢(糧築齋繭鬱顧構築廠膚) = 築窪製顧鹹簾淵壓構顧 鹽構淵鹽獵獵餘積餘願 (鏇膚壓蓋憲獵艱齋遞餘, 夢蓋衊觸膚鹽築壓醖構 ~ 築窪蓋衊淵繭構衊鏇製) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 選廠網餘網糧齋衊顧夢(糧築齋繭鬱顧構築廠膚) = 鏇憲餘鏇範獵鏇齋築壓 鹽構淵鹽獵獵餘積餘願 (鏇膚壓蓋憲獵艱齋遞餘, 蓋積鹹願鹽鹹築蓋夢窪 ~ 衊獵願鹹艱夢鑰鹽憲遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用